Which has higher valuation and earnings, AZN or NVS?

Novartis has lower revenue, but higher earnings than Astrazeneca. Novartis is trading at a lower price-to-earnings ratio than Astrazeneca, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Astrazeneca $58.74B 4.62 $10.23B $6.66 26.26 Novartis $54.53B 5.15 $13.98B $6.98 21.08

Is AZN or NVS more profitable?

Novartis has a net margin of 24.87% compared to Astrazeneca's net margin of 17.19%. Novartis' return on equity of 38.82% beat Astrazeneca's return on equity. Company Net Margins Return on Equity Return on Assets Astrazeneca 17.19% 30.86% 12.68% Novartis 24.87% 38.82% 15.16%

Does the media refer more to AZN or NVS?

In the previous week, Astrazeneca had 7 more articles in the media than Novartis. MarketBeat recorded 8 mentions for Astrazeneca and 1 mentions for Novartis. Astrazeneca's average media sentiment score of 0.91 beat Novartis' score of 0.53 indicating that Astrazeneca is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Astrazeneca 5 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Novartis 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is NVS or NVO more profitable?

Novo Nordisk A/S has a net margin of 37.23% compared to Novartis' net margin of 24.87%. Novo Nordisk A/S's return on equity of 63.31% beat Novartis' return on equity. Company Net Margins Return on Equity Return on Assets Novartis 24.87% 38.82% 15.16% Novo Nordisk A/S 37.23% 63.31% 22.19%

Does the media prefer NVS or NVO?

In the previous week, Novo Nordisk A/S had 35 more articles in the media than Novartis. MarketBeat recorded 36 mentions for Novo Nordisk A/S and 1 mentions for Novartis. Novo Nordisk A/S's average media sentiment score of 0.78 beat Novartis' score of 0.53 indicating that Novo Nordisk A/S is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Novartis 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Novo Nordisk A/S 18 Very Positive mention(s) 7 Positive mention(s) 5 Neutral mention(s) 4 Negative mention(s) 2 Very Negative mention(s) Positive

Which has higher earnings and valuation, SNY or NVS?

Novartis has higher revenue and earnings than Sanofi. Sanofi is trading at a lower price-to-earnings ratio than Novartis, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Sanofi $49.35B 2.08 $8.84B $3.58 11.84 Novartis $54.53B 5.15 $13.98B $6.98 21.08

Is SNY or NVS more profitable?

Novartis has a net margin of 24.87% compared to Sanofi's net margin of 16.95%. Novartis' return on equity of 38.82% beat Sanofi's return on equity. Company Net Margins Return on Equity Return on Assets Sanofi 16.95% 13.39% 7.58% Novartis 24.87% 38.82% 15.16%

Does the media prefer SNY or NVS?

In the previous week, Sanofi had 2 more articles in the media than Novartis. MarketBeat recorded 3 mentions for Sanofi and 1 mentions for Novartis. Novartis' average media sentiment score of 0.53 beat Sanofi's score of 0.37 indicating that Novartis is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sanofi 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Novartis 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation and earnings, GSK or NVS?

Novartis has higher revenue and earnings than GSK. GSK is trading at a lower price-to-earnings ratio than Novartis, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio GSK $43.07B 2.39 $7.54B $3.85 13.18 Novartis $54.53B 5.15 $13.98B $6.98 21.08

Is GSK or NVS more profitable?

Novartis has a net margin of 24.87% compared to GSK's net margin of 17.82%. GSK's return on equity of 44.28% beat Novartis' return on equity. Company Net Margins Return on Equity Return on Assets GSK 17.82% 44.28% 11.49% Novartis 24.87% 38.82% 15.16%

Does the media favor GSK or NVS?

In the previous week, GSK had 8 more articles in the media than Novartis. MarketBeat recorded 9 mentions for GSK and 1 mentions for Novartis. GSK's average media sentiment score of 0.90 beat Novartis' score of 0.53 indicating that GSK is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment GSK 5 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Novartis 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation and earnings, ARGX or NVS?

Novartis has higher revenue and earnings than argenex. Novartis is trading at a lower price-to-earnings ratio than argenex, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio argenex $4.25B 12.85 $1.29B $22.46 39.08 Novartis $54.53B 5.15 $13.98B $6.98 21.08

Is ARGX or NVS more profitable?

argenex has a net margin of 31.31% compared to Novartis' net margin of 24.87%. argenex's return on equity of 44.37% beat Novartis' return on equity. Company Net Margins Return on Equity Return on Assets argenex 31.31% 44.37% 37.55% Novartis 24.87% 38.82% 15.16%

Does the media favor ARGX or NVS?

In the previous week, argenex and argenex both had 1 articles in the media. argenex's average media sentiment score of 0.65 beat Novartis' score of 0.53 indicating that argenex is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment argenex 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Novartis 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Novartis (NVS) Competitors

$147.17 +0.09 (+0.06%)

Closing price 06/18/2026 03:59 PM Eastern

Extended Trading

$147.65 +0.48 (+0.32%)

As of 06/18/2026 07:10 PM Eastern

Compare

NVS vs. AZN, NVO, SNY, GSK, and ARGX

Should you buy Novartis stock or one of its competitors? MarketBeat compares Novartis with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Novartis include Astrazeneca (AZN), Novo Nordisk A/S (NVO), Sanofi (SNY), GSK (GSK), and argenex (ARGX). These companies are all part of the "pharmaceutical products" industry.

How does Novartis compare to Astrazeneca?

Astrazeneca (NYSE:AZN) and Novartis (NYSE:NVS) are both large-cap pharmaceutical products companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, dividends, media sentiment, valuation, profitability, institutional ownership, risk and analyst recommendations.

Novartis has lower revenue, but higher earnings than Astrazeneca. Novartis is trading at a lower price-to-earnings ratio than Astrazeneca, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Astrazeneca	$58.74B	4.62	$10.23B	$6.66	26.26
Novartis	$54.53B	5.15	$13.98B	$6.98	21.08

Novartis has a net margin of 24.87% compared to Astrazeneca's net margin of 17.19%. Novartis' return on equity of 38.82% beat Astrazeneca's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Astrazeneca	17.19%	30.86%	12.68%
Novartis	24.87%	38.82%	15.16%

Astrazeneca has a beta of 0.25, meaning that its stock price is 75% less volatile than the broader market. Comparatively, Novartis has a beta of 0.46, meaning that its stock price is 54% less volatile than the broader market.

Astrazeneca pays an annual dividend of $4.34 per share and has a dividend yield of 2.5%. Novartis pays an annual dividend of $3.08 per share and has a dividend yield of 2.1%. Astrazeneca pays out 65.2% of its earnings in the form of a dividend. Novartis pays out 44.1% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

In the previous week, Astrazeneca had 7 more articles in the media than Novartis. MarketBeat recorded 8 mentions for Astrazeneca and 1 mentions for Novartis. Astrazeneca's average media sentiment score of 0.91 beat Novartis' score of 0.53 indicating that Astrazeneca is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Astrazeneca	5 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Novartis	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Astrazeneca presently has a consensus price target of $205.33, suggesting a potential upside of 17.42%. Novartis has a consensus price target of $141.20, suggesting a potential downside of 4.06%. Given Astrazeneca's stronger consensus rating and higher probable upside, analysts clearly believe Astrazeneca is more favorable than Novartis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Astrazeneca	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.85
Novartis	2 Sell rating(s)	7 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.31

20.4% of Astrazeneca shares are held by institutional investors. Comparatively, 13.1% of Novartis shares are held by institutional investors. 0.0% of Novartis shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Astrazeneca and Novartis tied by winning 9 of the 18 factors compared between the two stocks.

How does Novartis compare to Novo Nordisk A/S?

Novartis (NYSE:NVS) and Novo Nordisk A/S (NYSE:NVO) are both large-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, institutional ownership, media sentiment, valuation, profitability and risk.

Novartis has a beta of 0.46, suggesting that its share price is 54% less volatile than the broader market. Comparatively, Novo Nordisk A/S has a beta of 0.78, suggesting that its share price is 22% less volatile than the broader market.

In the previous week, Novo Nordisk A/S had 35 more articles in the media than Novartis. MarketBeat recorded 36 mentions for Novo Nordisk A/S and 1 mentions for Novartis. Novo Nordisk A/S's average media sentiment score of 0.78 beat Novartis' score of 0.53 indicating that Novo Nordisk A/S is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Novartis	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Novo Nordisk A/S	18 Very Positive mention(s)	7 Positive mention(s)	5 Neutral mention(s)	4 Negative mention(s)	2 Very Negative mention(s)	Positive

Novartis pays an annual dividend of $3.08 per share and has a dividend yield of 2.1%. Novo Nordisk A/S pays an annual dividend of $1.75 per share and has a dividend yield of 4.1%. Novartis pays out 44.1% of its earnings in the form of a dividend. Novo Nordisk A/S pays out 41.1% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Novo Nordisk A/S is clearly the better dividend stock, given its higher yield and lower payout ratio.

Novo Nordisk A/S has lower revenue, but higher earnings than Novartis. Novo Nordisk A/S is trading at a lower price-to-earnings ratio than Novartis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Novartis	$54.53B	5.15	$13.98B	$6.98	21.08
Novo Nordisk A/S	$46.80B	4.12	$15.51B	$4.26	10.14

Novartis currently has a consensus price target of $141.20, indicating a potential downside of 4.06%. Novo Nordisk A/S has a consensus price target of $65.56, indicating a potential upside of 51.77%. Given Novo Nordisk A/S's higher probable upside, analysts plainly believe Novo Nordisk A/S is more favorable than Novartis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Novartis	2 Sell rating(s)	7 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.31
Novo Nordisk A/S	1 Sell rating(s)	17 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.17

Novo Nordisk A/S has a net margin of 37.23% compared to Novartis' net margin of 24.87%. Novo Nordisk A/S's return on equity of 63.31% beat Novartis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Novartis	24.87%	38.82%	15.16%
Novo Nordisk A/S	37.23%	63.31%	22.19%

13.1% of Novartis shares are owned by institutional investors. Comparatively, 11.5% of Novo Nordisk A/S shares are owned by institutional investors. 0.0% of Novartis shares are owned by company insiders. Comparatively, 0.1% of Novo Nordisk A/S shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Novo Nordisk A/S beats Novartis on 11 of the 18 factors compared between the two stocks.

How does Novartis compare to Sanofi?

Sanofi (NASDAQ:SNY) and Novartis (NYSE:NVS) are both large-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, dividends, risk, profitability, media sentiment and valuation.

Sanofi has a beta of 0.34, meaning that its stock price is 66% less volatile than the broader market. Comparatively, Novartis has a beta of 0.46, meaning that its stock price is 54% less volatile than the broader market.

14.0% of Sanofi shares are held by institutional investors. Comparatively, 13.1% of Novartis shares are held by institutional investors. 1.0% of Sanofi shares are held by insiders. Comparatively, 0.0% of Novartis shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Sanofi currently has a consensus target price of $51.00, indicating a potential upside of 20.34%. Novartis has a consensus target price of $141.20, indicating a potential downside of 4.06%. Given Sanofi's stronger consensus rating and higher probable upside, analysts clearly believe Sanofi is more favorable than Novartis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sanofi	0 Sell rating(s)	10 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	2.47
Novartis	2 Sell rating(s)	7 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.31

Sanofi pays an annual dividend of $1.76 per share and has a dividend yield of 4.2%. Novartis pays an annual dividend of $3.08 per share and has a dividend yield of 2.1%. Sanofi pays out 49.2% of its earnings in the form of a dividend. Novartis pays out 44.1% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

In the previous week, Sanofi had 2 more articles in the media than Novartis. MarketBeat recorded 3 mentions for Sanofi and 1 mentions for Novartis. Novartis' average media sentiment score of 0.53 beat Sanofi's score of 0.37 indicating that Novartis is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sanofi	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Novartis	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Novartis has a net margin of 24.87% compared to Sanofi's net margin of 16.95%. Novartis' return on equity of 38.82% beat Sanofi's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sanofi	16.95%	13.39%	7.58%
Novartis	24.87%	38.82%	15.16%

Novartis has higher revenue and earnings than Sanofi. Sanofi is trading at a lower price-to-earnings ratio than Novartis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sanofi	$49.35B	2.08	$8.84B	$3.58	11.84
Novartis	$54.53B	5.15	$13.98B	$6.98	21.08

Summary

Novartis beats Sanofi on 12 of the 19 factors compared between the two stocks.

How does Novartis compare to GSK?

GSK (NYSE:GSK) and Novartis (NYSE:NVS) are both large-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, media sentiment, risk, institutional ownership, earnings, profitability, valuation and analyst recommendations.

GSK pays an annual dividend of $1.81 per share and has a dividend yield of 3.6%. Novartis pays an annual dividend of $3.08 per share and has a dividend yield of 2.1%. GSK pays out 47.0% of its earnings in the form of a dividend. Novartis pays out 44.1% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

Novartis has higher revenue and earnings than GSK. GSK is trading at a lower price-to-earnings ratio than Novartis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GSK	$43.07B	2.39	$7.54B	$3.85	13.18
Novartis	$54.53B	5.15	$13.98B	$6.98	21.08

15.7% of GSK shares are owned by institutional investors. Comparatively, 13.1% of Novartis shares are owned by institutional investors. 10.0% of GSK shares are owned by insiders. Comparatively, 0.0% of Novartis shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

GSK currently has a consensus target price of $53.00, indicating a potential upside of 4.41%. Novartis has a consensus target price of $141.20, indicating a potential downside of 4.06%. Given GSK's higher possible upside, equities research analysts plainly believe GSK is more favorable than Novartis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GSK	3 Sell rating(s)	4 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.00
Novartis	2 Sell rating(s)	7 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.31

In the previous week, GSK had 8 more articles in the media than Novartis. MarketBeat recorded 9 mentions for GSK and 1 mentions for Novartis. GSK's average media sentiment score of 0.90 beat Novartis' score of 0.53 indicating that GSK is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GSK	5 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Novartis	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

GSK has a beta of 0.36, meaning that its share price is 64% less volatile than the broader market. Comparatively, Novartis has a beta of 0.46, meaning that its share price is 54% less volatile than the broader market.

Novartis has a net margin of 24.87% compared to GSK's net margin of 17.82%. GSK's return on equity of 44.28% beat Novartis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GSK	17.82%	44.28%	11.49%
Novartis	24.87%	38.82%	15.16%

Summary

Novartis beats GSK on 11 of the 18 factors compared between the two stocks.

How does Novartis compare to argenex?

argenex (NASDAQ:ARGX) and Novartis (NYSE:NVS) are both large-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, earnings, institutional ownership, profitability, analyst recommendations, dividends and media sentiment.

In the previous week, argenex and argenex both had 1 articles in the media. argenex's average media sentiment score of 0.65 beat Novartis' score of 0.53 indicating that argenex is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
argenex	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Novartis	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

60.3% of argenex shares are owned by institutional investors. Comparatively, 13.1% of Novartis shares are owned by institutional investors. 2.4% of argenex shares are owned by company insiders. Comparatively, 0.0% of Novartis shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

argenex has a net margin of 31.31% compared to Novartis' net margin of 24.87%. argenex's return on equity of 44.37% beat Novartis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
argenex	31.31%	44.37%	37.55%
Novartis	24.87%	38.82%	15.16%

argenex has a beta of 0.47, indicating that its share price is 53% less volatile than the broader market. Comparatively, Novartis has a beta of 0.46, indicating that its share price is 54% less volatile than the broader market.

Novartis has higher revenue and earnings than argenex. Novartis is trading at a lower price-to-earnings ratio than argenex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
argenex	$4.25B	12.85	$1.29B	$22.46	39.08
Novartis	$54.53B	5.15	$13.98B	$6.98	21.08

argenex currently has a consensus price target of $1,019.50, indicating a potential upside of 16.15%. Novartis has a consensus price target of $141.20, indicating a potential downside of 4.06%. Given argenex's stronger consensus rating and higher possible upside, equities research analysts clearly believe argenex is more favorable than Novartis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
argenex	0 Sell rating(s)	4 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	2.92
Novartis	2 Sell rating(s)	7 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.31

Summary

argenex beats Novartis on 14 of the 16 factors compared between the two stocks.

Get Novartis News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NVS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NVS vs. The Competition

Export

Metric	Novartis	Large Cap Pharma Industry	Medical Sector	NYSE Exchange
Market Cap	$280.65B	$302.55B	$6.43B	$23.21B
Dividend Yield	2.09%	2.85%	2.68%	4.06%
P/E Ratio	21.08	27.04	20.90	28.67
Price / Sales	5.15	4.99	529.30	22.84
Price / Cash	13.69	12.90	27.92	18.67
Price / Book	6.68	7.72	10.81	4.69
Net Income	$13.98B	$11.61B	$3.57B	$1.08B
7 Day Performance	-3.83%	-3.12%	0.72%	-0.82%
1 Month Performance	-3.08%	-1.95%	0.41%	1.07%
1 Year Performance	27.29%	18.96%	29.34%	25.02%

Novartis Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NVS Novartis	2.5965 of 5 stars	$147.17 +0.1%	$141.20 -4.1%	+27.3%	$280.65B	$54.53B	21.08	75,267
AZN Astrazeneca	4.7046 of 5 stars	$178.87 -2.5%	$205.33 +14.8%	+25.0%	$277.42B	$58.74B	26.86	96,100
NVO Novo Nordisk A/S	4.3563 of 5 stars	$42.73 +1.3%	$65.56 +53.4%	-41.4%	$190.78B	$46.80B	10.03	69,505	Analyst Upgrade
SNY Sanofi	4.5165 of 5 stars	$43.56 -2.6%	$51.00 +17.1%	-11.5%	$105.61B	$49.35B	12.17	74,846
GSK GSK	3.7591 of 5 stars	$51.22 -0.1%	$53.00 +3.5%	+33.6%	$103.93B	$43.07B	13.31	66,841	Dividend Cut Options Volume Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:NVS) was last updated on 6/21/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Novartis (NVS) Competitors

NVS vs. AZN, NVO, SNY, GSK, and ARGX

How does Novartis compare to Astrazeneca?

Summary

How does Novartis compare to Novo Nordisk A/S?

Summary

How does Novartis compare to Sanofi?

Summary

How does Novartis compare to GSK?

Summary

How does Novartis compare to argenex?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NVS vs. The Competition

Novartis Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Novartis (NVS) Competitors

NVS vs. AZN, NVO, SNY, GSK, and ARGX

How does Novartis compare to Astrazeneca?

Which has higher valuation and earnings, AZN or NVS?

Is AZN or NVS more profitable?

Which has more risk & volatility, AZN or NVS?

Is AZN or NVS a better dividend stock?

Does the media refer more to AZN or NVS?

Do analysts prefer AZN or NVS?

Do insiders and institutionals believe in AZN or NVS?

Summary

How does Novartis compare to Novo Nordisk A/S?

Which has more volatility & risk, NVS or NVO?

Does the media prefer NVS or NVO?

Is NVS or NVO a better dividend stock?

Which has higher earnings and valuation, NVS or NVO?

Do analysts prefer NVS or NVO?

Is NVS or NVO more profitable?

Do insiders & institutionals believe in NVS or NVO?

Summary

How does Novartis compare to Sanofi?

Which has more volatility and risk, SNY or NVS?

Do insiders & institutionals have more ownership in SNY or NVS?

Do analysts rate SNY or NVS?

Is SNY or NVS a better dividend stock?

Does the media prefer SNY or NVS?

Is SNY or NVS more profitable?

Which has higher earnings and valuation, SNY or NVS?

Summary

How does Novartis compare to GSK?

Is GSK or NVS a better dividend stock?

Which has higher valuation and earnings, GSK or NVS?

Do institutionals and insiders hold more shares of GSK or NVS?

Do analysts prefer GSK or NVS?

Does the media favor GSK or NVS?

Which has more risk and volatility, GSK or NVS?

Is GSK or NVS more profitable?

Summary

How does Novartis compare to argenex?

Does the media favor ARGX or NVS?

Do institutionals and insiders believe in ARGX or NVS?

Is ARGX or NVS more profitable?

Which has more risk and volatility, ARGX or NVS?

Which has higher valuation and earnings, ARGX or NVS?

Do analysts prefer ARGX or NVS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NVS vs. The Competition

Novartis Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools